Our Mission

To discover novel therapeutics that will stop the progression
of neurodegenerative diseases by targeting their underlying causes.

Our Programs

CURRENT CLINICAL TRIALS 

UCB0599 Phase 1b in PD Patients

News

Neuropore Receives a Grant from The ALS Association

February 17, 2020

Neuropore Therapies, Inc., a clinical stage biopharmaceutical company announced today that it has been awarded a grant from The ALS Association to support the preclinical evaluation and development of its leading Toll-Like Receptor 2 (TLR2) antagonist for the treatment of amyotrophic lateral sclerosis.

See All News

NPT® Publications

Neuropore publishes paper describing preclinical in vivo characterization of  small molecule targeting α-synuclein as a potential Parkinson's disease therapeutic
November 2nd, 2018

Report in Scientific Reports, describes the beneficial effects of NPT200-11 on multiple disease relevant endpoints in a transgenic mouse model of Parkinson's disease.

See All Publications

 

 

A team poised for success

About Our Team

Our Partners




Corporate

UCB Logo


Foundations & Academic InstitutionsSEE ALL

The Michael J. Fox Foundation for Parkinson's Research
Albert Einstein College of Medicine
University of Sydney

Connect with Neuropore